2013 delivered in a big way for each of the major deal-making outlets. We observed nearly three times the number of IPOs as in 2012. The M&A market opened up with the total dollars spent on acquisitions reaching the highest in five years. Strong deal terms with large upfront payments for early stage assets were also seen in 2013 as exemplified with Moderna’s $240M upfront from Astrazeneca and Oncomed’s $177M upfront from Celgene. Will these upward trends continue? How will these changing dynamics impact dealmaking in the coming year? What do dealmakers expect will be the result in 2014?
Campbell Alliance and BIO are pleased to present updated findings from two unique forward-looking measures of dealmaking in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives, business development professionals, and financial institutions, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more. Now in its sixth year, new analysis in 2014 will include year-over-year trends, additional deal metrics, and broader M&A data. Incorporating a global perspective, a highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they position themselves to make that next big deal.
Sponsored by Campbell Alliance
Open to Education and Exhibition Access, Convention Access, Convention Access & Partnering
Session ID: 2586